gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE American · PTHSHealthcareBiotechnology

Pelthos Therapeutics Inc. (PTHS)

$9.30−8.37%
Close Nov 5, 2026 · split-adjusted
Nov 5, 2026$9.55▼ 72.52% in range
Nov 4, 2025Low $9.40 · High $37.42Nov 5, 2026
What changed · written from our data
As of Nov 5, 2026

Pelthos Therapeutics closed at $9.30 on Nov 5, down 8.37%, within 0.0% of its 52-week closing low. Volume of 31.1K shares was 0.42× its 20-day average (below normal).

Split-adjusted performance: -55.7% over one month, -62.8% over six months.

In the quarter ended Jun 30, 2026, revenue was $15.60M, with a net margin of -150.1%.

Short interest was 142.2K shares at the Oct 15 settlement, up 36.0% from the prior report (8.6% of float, 3.0 days to cover).

Market cap$36.6M3.9M shares
Revenue · quarter$15.6M—
Diluted EPS$-6.62—
P/E · TTM—P/S 0.8×
Net margin-150.1%Gross 76.9%
Dividend yieldNone
52-week range9.30 – 37.42−75.1% from high
Volume31.1K0.42× 20-day avg
Volatility · 60d141.3%Annualised
Short % of float8.6%3.0 days to cover
Net cash-$45.7MCash $24.2M
Next earnings—Not scheduled
Split-adjusted performance
1W −43.8%1M −55.7%3M −67.2%6M −62.8%YTD −70.0%1Y —3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum18
Revenue growth—
Net margin57
Value (low P/E)—
Size22

Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.

Short interest

Details →
Shares short142.3K+36.0% vs prior
Days to cover3.0Settled Oct 15
% of float8.6%
Short vol. 10d70.2%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
PTHSPelthos Therapeutics$9.30−8.37%−62.8%—−150.1%—$36.6M
INMBINmune Bio$1.18−11.65%−17.8%———$36.4MCompare
EXOZeXoZymes$4.11−4.64%−58.9%———$38.2MCompare
ELUTElutia$0.7509−1.15%−24.8%−11.6%−315.0%0.6$33.3MCompare
LONALeonaBio$4.34−4.93%−56.0%———$40.9MCompare
CRBUCaribou Biosciences$0.4123−7.22%−78.1%−43.8%−1619.9%—$44.2MCompare
IMAImageneBio$4.17+1.59%−29.5%———$47.3MCompare
TILInstil Bio$6.990.00%−13.0%———$47.4MCompare
ALGSAligos Therapeutics$4.51−10.16%−25.2%+2778.5%−5.4%—$28.2MCompare

News about Pelthos Therapeutics

All news →
Pelthos Therapeutics Announces 2026 Annual Meeting of StockholdersGlobeNewswire Inc. · Jul 24, 2026NeutralPelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare ConferenceGlobeNewswire Inc. · May 28, 2026▲ Positive

Quick answers

What does Pelthos Therapeutics do?
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S.
What is PTHS's market cap?
$36.57M, based on the Nov 5 close of $9.30.
Does Pelthos Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of PTHS is sold short?
142.2K shares, 8.6% of float, as of Oct 15, 2026.
What sector is PTHS in?
Healthcare, in the Biotechnology industry.

About Pelthos Therapeutics

Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.

HQ: Durham, NC92 employeesListed Feb 16, 2024pelthos.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology